메뉴 건너뛰기




Volumn 3, Issue 4, 2013, Pages 406-417

First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement

(28)  Tabernero, Josep a   Shapiro, Geoffrey I d   LoRusso, Patricia M g   Cervantes, Andres b   Schwartz, Gary K h   Weiss, Glen J i   Paz Ares, Luis c   Cho, Daniel C e   Infante, Jeffrey R j   Alsina, Maria a   Gounder, Mrinal M h   Falzone, Rick f   Harrop, Jamie f   White, Amy C Seila f   Toudjarska, Iva f   Bumcrot, David f   Meyers, Rachel E f   Hinkle, Gregory f   Svrzikapa, Nenad f   Hutabarat, Renta M f   more..


Author keywords

[No Author keywords available]

Indexed keywords

ALN VSP; ALPHA INTERFERON; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYZINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KINESIN; PARACETAMOL; RANITIDINE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

EID: 84877120847     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0429     Document Type: Article
Times cited : (623)

References (44)
  • 1
    • 0032545933 scopus 로고    scopus 로고
    • Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans
    • Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
    • (1998) Nature , vol.391 , pp. 806-811
    • Fire, A.1    Xu, S.2    Montgomery, M.K.3    Kostas, S.A.4    Driver, S.E.5    Mello, C.C.6
  • 2
    • 0035942736 scopus 로고    scopus 로고
    • Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
    • Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
    • (2001) Nature , vol.411 , pp. 494-498
    • Elbashir, S.M.1    Harborth, J.2    Lendeckel, W.3    Yalcin, A.4    Weber, K.5    Tuschl, T.6
  • 3
  • 7
    • 34848918210 scopus 로고    scopus 로고
    • Impact of tumor-specifi c targeting on the biodistribution and effi cacy of siRNA nanoparticles measured by multimodality in vivo imaging
    • Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specifi c targeting on the biodistribution and effi cacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A 2007; 104: 15549-54.
    • (2007) Proc Natl Acad Sci U S A , vol.104 , pp. 15549-15554
    • Bartlett, D.W.1    Su, H.2    Hildebrandt, I.J.3    Weber, W.A.4    Davis, M.E.5
  • 8
    • 25444482607 scopus 로고    scopus 로고
    • Sequence-specifi c knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma
    • Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specifi c knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-92.
    • (2005) Cancer Res , vol.65 , pp. 8984-8992
    • Hu-Lieskovan, S.1    Heidel, J.D.2    Bartlett, D.W.3    Davis, M.E.4    Triche, T.J.5
  • 9
    • 77951132901 scopus 로고    scopus 로고
    • Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
    • Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-70.
    • (2010) Nature , vol.464 , pp. 1067-1070
    • Davis, M.E.1    Zuckerman, J.E.2    Choi, C.H.3    Seligson, D.4    Tolcher, A.5    Alabi, C.A.6
  • 10
    • 34447122735 scopus 로고    scopus 로고
    • Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
    • Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 2007; 7: 47-55.
    • (2007) Clin Exp Med , vol.7 , pp. 47-55
    • Koldehoff, M.1    Steckel, N.K.2    Beelen, D.W.3    Elmaagacli, A.H.4
  • 12
    • 77954243341 scopus 로고    scopus 로고
    • Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
    • Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010; 18: 1357-64.
    • (2010) Mol Ther , vol.18 , pp. 1357-1364
    • Akinc, A.1    Querbes, W.2    De, S.3    Qin, J.4    Frank-Kamenetsky, M.5    Jayaprakash, K.N.6
  • 14
    • 50149101511 scopus 로고    scopus 로고
    • Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
    • Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105: 11915-20.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , pp. 11915-11920
    • Frank-Kamenetsky, M.1    Grefhorst, A.2    Anderson, N.N.3    Racie, T.S.4    Bramlage, B.5    Akinc, A.6
  • 15
    • 65649085603 scopus 로고    scopus 로고
    • Confi rming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
    • Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confi rming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-73.
    • (2009) J Clin Invest , vol.119 , pp. 661-673
    • Judge, A.D.1    Robbins, M.2    Tavakoli, I.3    Levi, J.4    Hu, L.5    Fronda, A.6
  • 16
    • 79959958353 scopus 로고    scopus 로고
    • Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products
    • Wahl O, Oswald M, Tretzel L, Herres E, Arend J, Efferth T. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. Curr Med Chem 2011; 18: 3136-55.
    • (2011) Curr Med Chem , vol.18 , pp. 3136-3155
    • Wahl, O.1    Oswald, M.2    Tretzel, L.3    Herres, E.4    Arend, J.5    Efferth, T.6
  • 17
    • 52749097817 scopus 로고    scopus 로고
    • Progress on kinesin spindle protein inhibitors as anticancer agents
    • Zhang Y, Xu W. Progress on kinesin spindle protein inhibitors as anticancer agents. Anticancer Agents Med Chem 2008; 8: 698-704.
    • (2008) Anticancer Agents Med Chem , vol.8 , pp. 698-704
    • Zhang, Y.1    Xu, W.2
  • 18
    • 20144389695 scopus 로고    scopus 로고
    • Sequence-specifi c potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7
    • Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, et al. Sequence-specifi c potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 2005; 11: 263-70.
    • (2005) Nat Med , vol.11 , pp. 263-270
    • Hornung, V.1    Guenthner-Biller, M.2    Bourquin, C.3    Ablasser, A.4    Schlee, M.5    Uematsu, S.6
  • 19
    • 22344454846 scopus 로고    scopus 로고
    • Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
    • Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005; 23: 457-62.
    • (2005) Nat Biotechnol , vol.23 , pp. 457-462
    • Judge, A.D.1    Sood, V.2    Shaw, J.R.3    Fang, D.4    McClintock, K.5    MacLachlan, I.6
  • 21
    • 0027050420 scopus 로고
    • Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
    • Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774-81.
    • (1992) Cancer Res , vol.52 , pp. 6774-6781
    • Huang, S.K.1    Mayhew, E.2    Gilani, S.3    Lasic, D.D.4    Martin, F.J.5    Papahadjopoulos, D.6
  • 22
    • 0023280158 scopus 로고
    • Fate and behavior of liposomes in vivo: A review of controlling factors
    • Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 1987; 3: 123-93.
    • (1987) Crit Rev Ther Drug Carrier Syst , vol.3 , pp. 123-193
    • Senior, J.H.1
  • 23
    • 0034000453 scopus 로고    scopus 로고
    • Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
    • Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
    • (2000) J Control Release , vol.65 , pp. 271-284
    • Maeda, H.1    Wu, J.2    Sawa, T.3    Matsumura, Y.4    Hori, K.5
  • 24
  • 25
    • 42549088324 scopus 로고    scopus 로고
    • Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck
    • Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 2008; 26: 257-64.
    • (2008) Invest New Drugs , vol.26 , pp. 257-264
    • Tang, P.A.1    Siu, L.L.2    Chen, E.X.3    Hotte, S.J.4    Chia, S.5    Schwarz, J.K.6
  • 26
    • 79955627902 scopus 로고    scopus 로고
    • A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
    • Burris HA, Jones SF, Williams DD, Kathman SJ, Hodge JP, Pandite L, et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011; 29: 467-72.
    • (2011) Invest New Drugs , vol.29 , pp. 467-472
    • Burris, H.A.1    Jones, S.F.2    Williams, D.D.3    Kathman, S.J.4    Hodge, J.P.5    Pandite, L.6
  • 28
    • 9144247189 scopus 로고    scopus 로고
    • Therapeutic silencing of an endogenous gene by systemic administration of modifi ed siRNAs
    • Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modifi ed siRNAs. Nature 2004; 432: 173-8.
    • (2004) Nature , vol.432 , pp. 173-178
    • Soutschek, J.1    Akinc, A.2    Bramlage, B.3    Charisse, K.4    Constien, R.5    Donoghue, M.6
  • 29
    • 80052174164 scopus 로고    scopus 로고
    • Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention
    • Szebeny J, Muggia F, Gabizo A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 2011; 63: 1020-30.
    • (2011) Adv Drug Deliv Rev , vol.63 , pp. 1020-1030
    • Szebeny, J.1    Muggia, F.2    Gabizo, A.3    Barenholz, Y.4
  • 30
    • 14644415949 scopus 로고    scopus 로고
    • Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    • Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028-43.
    • (2005) J Clin Oncol , vol.23 , pp. 1028-1043
    • Rini, B.I.1    Small, E.J.2
  • 31
    • 37549006796 scopus 로고    scopus 로고
    • Clinical and biological signifi cance of vascular endothelial growth factor in endometrial cancer
    • Kamat AA, Merritt WM, Coffey D, Lin YG, Patel PR, Broaddus R, et al. Clinical and biological signifi cance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487-95.
    • (2007) Clin Cancer Res , vol.13 , pp. 7487-7495
    • Kamat, A.A.1    Merritt, W.M.2    Coffey, D.3    Lin, Y.G.4    Patel, P.R.5    Broaddus, R.6
  • 32
    • 79958037593 scopus 로고    scopus 로고
    • New treatment options for patients with advanced neuroendocrine tumors
    • Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr Treatment Options Oncol 2011; 12: 136-48.
    • (2011) Curr Treatment Options Oncol , vol.12 , pp. 136-148
    • Chan, J.A.1    Kulke, M.H.2
  • 33
    • 77953915105 scopus 로고    scopus 로고
    • Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fi brous tumor
    • Park MS, Ravi V, Araujo DM. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/ solitary fi brous tumor. C urr Opin Oncol 2010; 22: 351-5.
    • (2010) C urr Opin Oncol , vol.22 , pp. 351-355
    • Park, M.S.1    Ravi, V.2    Araujo, D.M.3
  • 34
    • 33846478656 scopus 로고    scopus 로고
    • DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
    • O'Connor JPB, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-95.
    • (2007) Br J Cancer , vol.96 , pp. 189-195
    • O'Connor, J.P.B.1    Jackson, A.2    Parker, G.J.M.3    Jayson, G.C.4
  • 36
    • 0030568858 scopus 로고    scopus 로고
    • Increased expression of vascular endothelial growth factor and its receptors, fl t-1 and KDR/fl k-1, in regenerating rat liver
    • Mochida S, Ishikawa K, Inao M, Shibuya M, Fujiwara K. Increased expression of vascular endothelial growth factor and its receptors, fl t-1 and KDR/fl k-1, in regenerating rat liver. Biochem Biophys Res Comm 1996; 226: 176-9.
    • (1996) Biochem Biophys Res Comm , vol.226 , pp. 176-179
    • Mochida, S.1    Ishikawa, K.2    Inao, M.3    Shibuya, M.4    Fujiwara, K.5
  • 37
    • 0035013447 scopus 로고    scopus 로고
    • Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats
    • Shimizu H, Miyazaki M, Wakabayashi Y, Mitsuhashi N, Kato A, Ito H, et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. J Hepatol 2001; 34: 683-9.
    • (2001) J Hepatol , vol.34 , pp. 683-689
    • Shimizu, H.1    Miyazaki, M.2    Wakabayashi, Y.3    Mitsuhashi, N.4    Kato, A.5    Ito, H.6
  • 40
    • 70350002279 scopus 로고    scopus 로고
    • Adverse effects of anticancer agents that target the VEGF pathway
    • Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-77.
    • (2009) Nat Rev Clin Oncol , vol.6 , pp. 465-477
    • Chen, H.X.1    Cleck, J.N.2
  • 41
    • 34548068395 scopus 로고    scopus 로고
    • Infl ammatory breast cancer: Dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience
    • Thukral A, Thomasson DM, Chow CK, Eulate R, Wedam SB, Gupta SN, et al. Infl ammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab-initial experience. Radiology 2007; 244: 727-35.
    • (2007) Radiology , vol.244 , pp. 727-735
    • Thukral, A.1    Thomasson, D.M.2    Chow, C.K.3    Eulate, R.4    Wedam, S.B.5    Gupta, S.N.6
  • 42
    • 24944515034 scopus 로고    scopus 로고
    • Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamics measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study
    • Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamics measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-73.
    • (2005) J Clin Oncol , vol.23 , pp. 5464-5473
    • Liu, G.1    Rugo, H.S.2    Wilding, G.3    McShane, T.M.4    Evelhoch, J.L.5    Ng, C.6
  • 43
    • 79957949444 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study
    • Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29: 2259-65.
    • (2011) J Clin Oncol , vol.29 , pp. 2259-2265
    • Aghajanian, C.1    Sill, M.W.2    Darcy, K.M.3    Greer, B.4    McMeekin, D.S.5    Rose, P.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.